Tuesday, November 17, 2015
Print Current Session:
|
|
Tuesday
SESSION 5:
ADVANCES IN INTERVENTIONAL ONCOLOGY - PART 1
Moderators:Renee M. Moadel, MD / Andreas Kaubisch, MD
|
|
SESSION 5 SCHEDULE | |
8:00 AM - 8:10 AM | Curing Hepatitis: Changing Prevalence Of HCC |
Presenter(s):Kevin Kim, MD | |
View Slides in PDF | |
8:10 AM - 8:20 AM | Treatment Guidelines For HCC: Local Regional Therapy Is King |
Presenter(s):Riccardo Lencioni, MD, FSIR, EBIR | |
8:20 AM - 8:30 AM | Small Hepatomas: Surgery, Ablate Or TACE/Ablate |
Presenter(s):Joshua L. Weintraub, MD, FSIR | |
View Slides in PDF | |
8:30 AM - 8:40 AM | Intermediate Sized HCC: TACE/Ablate And Role Of Sorafanib |
Presenter(s):Jean Francois H. Geschwind, MD | |
View Slides in PDF | |
8:40 AM - 8:50 AM | Intermediate Sized HCC: Why I Treat With Y-90 |
Presenter(s):Riad Salem, MD, MBA | |
View Slides in PDF | |
8:50 AM - 9:00 AM | Large Tumors, Portal Vein Involvement, Childs C: Not Contraindicated For Interventional Therapy |
Presenter(s):Gregory J. Nadolski, MD | |
View Slides in PDF | |
9:00 AM - 9:10 AM | Management Of Hepatic Artery To PV Or HV Shunting |
Presenter(s):Edward Kim, MD | |
View Slides in PDF | |
9:10 AM - 9:20 AM | Use Of Biomarkers In Interventional Oncology |
Presenter(s):Kevin Kim, MD | |
View Slides in PDF | |
9:20 AM - 9:30 AM | Imaging Criteria To Assess Response Of Treatment |
Presenter(s):Victoria Chernyak, MD, MS / Riccardo Lencioni, MD, FSIR, EBIR | |
View Slides in PDF | |
9:30 AM - 9:40 AM | Trial Design For Investigating IR Therapies |
Presenter(s):Riad Salem, MD, MBA | |
View Slides in PDF | |
9:40 AM - 9:50 AM | Molecular Biology In Oncology |
Presenter(s):S. Nahum Goldberg, MD | |
9:50 AM - 10:10 AM | Panel Discussion |
10:10 AM - 10:30 AM | Break - Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 5 | |
previous | next |